Brief: Argenx Says Phase 3 Alkivia Trial Of Efgartigimod In Autoimmune Myositis Met Primary Endpoint
17/08/2026 06:25
BRIEF-Argenx Says Phase 3 Alkivia Trial Of Efgartigimod In Autoimmune Myositis Met Primary Endpoint Aug 17 (Reuters) - argenx SE ARGX.BR:
ARGENX ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE 3 ALKIVIA TRIAL OF EFGARTIGIMOD IN AUTOIMMUNE MYOSITIS
PHASE 3 STUDY MEETS PRIMARY ENDPOINT IN IMNM AND DM PATIENTS AT WEEK 52
EFGARTIGIMOD DEMONSTRATES EARLY AND SUSTAINED IMPROVEMENT OVER PLACEBO THROUGH ONE YEAR
EFGARTIGIMOD WELL-TOLERATED WITH CONSISTENT SAFETY PROFILE IN ALKIVIA STUDY
Source text: ID:nGNX7G5hYC
Further company coverage: ARGX.BR
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))